S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:DTIL

Precision BioSciences Stock Forecast, Price & News

$13.58
-1.06 (-7.24 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.43
Now: $13.58
$16.60
50-Day Range
$7.09
MA: $9.25
$14.64
52-Week Range
$4.45
Now: $13.58
$16.60
Volume3.82 million shs
Average Volume1.48 million shs
Market Capitalization$712.68 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

MarketRank

Overall MarketRank

1.52 out of 5 stars

Medical Sector

665th out of 1,926 stocks

Biological Products, Except Diagnostic Industry

87th out of 177 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DTIL
CUSIPN/A
CIKN/A
Phone919-314-5512
Employees223

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.24 million
Book Value$2.72 per share

Profitability

Net Income$-92,880,000.00
Net Margins-484.81%

Miscellaneous

Market Cap$712.68 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
$13.58
-1.06 (-7.24 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

How has Precision BioSciences' stock been impacted by Coronavirus?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DTIL shares have increased by 109.2% and is now trading at $13.58.
View which stocks have been most impacted by COVID-19
.

Is Precision BioSciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Precision BioSciences stock.
View analyst ratings for Precision BioSciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Precision BioSciences?

Wall Street analysts have given Precision BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Precision BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Precision BioSciences' CEO?

1,448 employees have rated Precision BioSciences CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Precision BioSciences' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Precision BioSciences
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) released its earnings results on Sunday, November, 15th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.66) by $0.16. The firm had revenue of $7.36 million for the quarter, compared to analysts' expectations of $4.25 million. Precision BioSciences had a negative return on equity of 105.74% and a negative net margin of 484.81%.
View Precision BioSciences' earnings history
.

What price target have analysts set for DTIL?

6 Wall Street analysts have issued 12-month target prices for Precision BioSciences' stock. Their forecasts range from $10.00 to $22.00. On average, they anticipate Precision BioSciences' stock price to reach $17.25 in the next year. This suggests a possible upside of 27.0% from the stock's current price.
View analysts' price targets for Precision BioSciences
or view Wall Street analyst' top-rated stocks.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 2,760,000 shares, an increase of 30.8% from the December 15th total of 2,110,000 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is currently 2.8 days. Currently, 6.3% of the shares of the stock are short sold.
View Precision BioSciences' Short Interest
.

Who are some of Precision BioSciences' key competitors?

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Mr. Matthew R. Kane, Co-Founder, CEO, Pres & Director (Age 43, Pay $562.1k)
  • Mr. Dario Scimeca, Gen. Counsel & Sec. (Age 45, Pay $319.96k)
  • Dr. Christopher R. Heery, Chief Medical Officer (Age 40, Pay $444.03k)
  • Dr. Jefferson J. Smith Ph.D., Co-Founder & CTO
  • Mr. Abid Ansari, Chief Financial Officer (Age 42)
  • Dr. David S. Thomson Ph.D., Chief Operating Officer (Age 59)
  • Dr. Derek Jantz Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 44)
  • Mr. John Alexander Kelly, Chief Corp. Affairs Officer & Investor Contact (Age 54)
  • Mr. Bruce Stevens, VP of Quality & Compliance
  • Ms. Heather King, Director of Marketing Communications & PR

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Pacer Advisors Inc. (0.01%). Company insiders that own Precision BioSciences stock include Christopher Heery, Global Strategic Fund Venbio and Tony Dung Ling Yao.
View institutional ownership trends for Precision BioSciences
.

Which major investors are buying Precision BioSciences stock?

DTIL stock was bought by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Precision BioSciences stock in the last two years include Christopher Heery, Global Strategic Fund Venbio, and Tony Dung Ling Yao.
View insider buying and selling activity for Precision BioSciences
or or view top insider-buying stocks.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $13.58.

How big of a company is Precision BioSciences?

Precision BioSciences has a market capitalization of $712.68 million and generates $22.24 million in revenue each year. The company earns $-92,880,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Precision BioSciences employs 223 workers across the globe.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is www.precisionbiosciences.com.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.